Teen becomes first patient cured of rare immune disease via gene editing

A 19-year-old from Kelowna, B.C., has made medical history as the first person cured of a rare immune disorder using a groundbreaking gene-editing technique. Ty Sperle no longer suffers from chronic granulomatous disease (CGD) after receiving an experimental treatment called prime editing, which corrected errors in his DNA. Doctors describe the outcome as a life-changing breakthrough for patients with genetic conditions.

Before the treatment, Sperle lived with constant risk. CGD weakened his immune system, leaving him vulnerable to severe infections. Daily antibiotics and antifungal drugs were necessary just to stay safe.

The procedure worked by fixing 'spelling mistakes' in his DNA. Scientists edited his cells in a lab, then returned the corrected versions to his body. Within weeks, his symptoms vanished, and his need for medication ended.

Dr. Stuart Turvey, Sperle's immunologist at BC Children's Hospital, called the result a 'miracle' and a long-awaited triumph for his patient. The hospital notes that while individual rare diseases are uncommon, they affect roughly one in three admitted patients when grouped together.

Provincial Health Minister Josie Osborne highlighted the achievement as a milestone for public healthcare, research, and international teamwork. The case was documented in the New England Journal of Medicine, marking the first successful use of prime editing to cure CGD. Since the December 2023 report, no further patients have been publicly recorded as receiving the same treatment.

Sperle's recovery offers tangible hope for others with genetic disorders as gene-editing technology progresses. His case proves that once-incurable conditions may now be treatable through precision medicine. The success also underscores the potential of public health systems to deliver cutting-edge care through global partnerships.